Compare Dolby Laboratories, Inc. (DLB) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Dolby Laboratories, Inc. trades at $58.65 (market cap $5.47B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: Dolby Laboratories, Inc. is far larger — about 2.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DLB | SLS | |
|---|---|---|
Market Cap | $5.47B | $2.27B |
Volume | 1,058,284 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $70.09 | $15.46 |
52-Week Low | $48.51 | $1.39 |
Typical Hold Time | 98 Days | — |
Enterprise Value | $4.85B | $2.14B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
